



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Characteristics associated with anti-HCV serological markers in prisoners in the state of Paraná, Brazil: a case-control study



Tânia Maria Pazin Marques Silva ^a, Lirane Elize Defante Ferreto^{a,*}, Franciele Ani Caovilla Follador^a, Ana Paula Vieira^a, Roberto Shigueyasu Yamada^b, Léia Carolina Lucio^a, Joana Perotta Titon^b, Renata Himovski Torres^c, Greicy César do Amaral^d, Harnoldo Colares Coelho^e

^a Western Paraná State University, Department of Life Sciences, Postgraduate Program in Applied Health Sciences, Francisco Beltrão, PR, Brazil

^b Western Paraná State University, Department of Life Sciences, General Surgery Residency Program, Francisco Beltrão, PR, Brazil.

^c Division of Public Security and Penitentiary Administration, Penitentiary Department, Curitiba, PR, Brazil.

^d 15th Health Division, State Health Office, Maringá, PR, Brazil

^e São Paulo State University, Department of Pharmacy, Ribeirão Preto, SP, Brazil

ARTICLE INFO

Article history:

Received 7 February 2019

Accepted 21 May 2019

Available online 20 June 2019

Keywords:

Hepatitis C

Risk factors

Prisoners

ABSTRACT

Background: The prison system in Paraná, Brazil, is experiencing serious problems related to the increasing number of prisoners. Control of hepatitis C virus (HCV) has become more intense because the incarcerated population is considered a high-risk group for contagious diseases due to the favorable conditions found in prisons for the spread of these morbidities. The objective of this study was to identify features associated with hepatitis C infection among male prisoners in correctional institutions of Paraná state, Brazil.

Methods: This was a case-control study (27 cases and 54 controls) of men incarcerated in 11 penitentiaries in Paraná, Brazil. Information was obtained through a questionnaire in a cross-sectional epidemiological survey on HCV infection during the period from May 2015 to December 2016. Eligible men were recruited after testing positive for anti-HCV antibodies. Cases and controls were selected based on serological results of enzyme-linked immunosorbent assays and were matched by age, location of the penitentiary, and time in prison. Logistic regression analysis was used to identify risk factors for HCV seropositivity.

Results: The main significant independent risk factor for the acquisition of HCV infection was the use of injectable drugs (OR = 4.00; 95%CI: 1.41–11.35; $p < 0.001$).

* Corresponding author.

E-mail address: liraneferreto@uol.com.br (L.E. Ferreto).

<https://doi.org/10.1016/j.bjid.2019.05.007>

1413-8670/© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusions: This study provides evidence that HCV infection is associated with drug use by this population. This information is pivotal for tailoring prevention programs and guiding specific socioeducational measures that aim to reduce or prevent HCV transmission within the prison setting.

© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Infection with type C viral hepatitis (HCV) is common among the prison population. It is also thought that incarceration itself may increase the risk of infection.^{1,2} This increased risk can be attributed to several causes, some associated with the prisons' structural and logistic problems and others with common problems or behaviors acquired during seclusion.^{2,3} Worldwide, it is estimated that approximately 15.1% of the 10.2 million incarcerated individuals are living with HCV.⁴ This rate is lower than the prevalence reported among prisoners in international studies, including studies in Italy (22.4%),⁵ Indonesia (34.1%)⁶ and Azerbaijan (38.2%).⁷

A wide variation in anti-HCV prevalence in the incarcerated population has been reported, ranging from 1% in a study carried out in Colatina, Brazil,⁸ to 47.4% in a study carried out in Australia.⁹ In a systematic review by Magri et al., hepatitis C prevalence ranged from 1% to 41% in Brazil.¹ This variation is associated with differences in geographical prison location, age, previous prison sentences, intravenous drug use, and even the quality of public health services available to the population, as well as with the different habits and high-risk behaviors in different geographical regions.¹⁰⁻¹³

Contamination by HCV in prisons has been linked to trauma-induced blood exposure, tattooing, intravenous drug use, and sexual activity.^{1,2,9,14-19} Confinement plus additional factors (sharing of material used for drug use, tattoos, piercings, and razor blades in addition to inadequate sterilization or reuse of medical or dental instruments) and deficiencies in health care also increase the vulnerability of prisoners to HIV/AIDS and other sexually transmitted infections.^{1,15,20-23}

Although there is some understanding of the scenarios that lead to the transmission of infectious diseases in prisons, epidemiological studies are still scarce for this population, especially in Brazil. Recently, a systematic review of studies from 1989 to 2014 conducted by Magri et al. on the prevalence of hepatitis C in prisoners in Brazil confirmed that none of the reviewed studies had been conducted in the state of Paraná, Brazil.¹ This study aimed to analyze the factors associated with hepatitis C infection among inmates of the Paraná prison system.

Materials and methods

This study was preceded by a cross-sectional survey carried out from May 2015 to December 2016 in 11 penitentiaries in Paraná state entitled "Prevalence of HIV and Hepatitis B and C in the prison population in the state of Paraná." Based on infor-

mation from the Penitentiary Department of Paraná (DEPEN, PR) at the time of the study, there were approximately 19,000 prisoners in 23 closed male prisons. Eleven of the 23 high-security closed prisons in six cities of the state (Francisco Beltrão, Londrina, Curitiba, São José dos Pinhais, Pinhais, and Piraquara) were included (Fig. 1). Our criteria for selecting the participating cities considered both the size of the cities as well as the presence of penitentiaries in closed regime. Three cities – all located in the state of Paraná – were then selected to take part in this study (Francisco Beltrão, a small-sized city, with a population of up to 100 thousand inhabitants; Londrina, a relatively large city, but with less than one million inhabitants; and Curitiba, the capital city with more than one million inhabitants).²⁴ In the closed-regime systems, inmates remain under daily supervision within the prison limits.

The sample size was calculated based on the expected prevalence of 50% HCV infection with 1% variation, a power of 80%, and 3% alpha error. The study population included 8,142 inmates, and the study sample size was 954 inmates. Approximately 25% more individuals (total: 1192 inmates) were added to account for anticipated loss due to participation refusal. Proportional stratified sampling was performed using each prison as a randomization unit. A total of 1132 prisoners were interviewed, with 60 losses or refusals (5%). On the day of data collection, the prisoners were sorted numerically in ascending order from the lists provided by the prison, and a list of random numbers was generated using the software Microsoft Excel[®] 2007. To be included, patients had to be (a) aged 18 years or older; (b) in custody, (c) able to consent for themselves, (d) able to be interviewed only by a researcher (without risk markers), and (e) able to understand spoken Portuguese. This study was carried out with the approval of the research Ethics Committee of the State University of West Paraná under approval number 810.574.

All eligible participants provided voluntary informed written consent prior to participation in the study and no compensation was provided. The treatment offered to the individuals who did not take part in the study was the same as that given to participants. Prisoners identified as HCV-positive received medical assistance. To investigate the prevalence of anti-HCV antibodies, we used a 3rd generation chemiluminescent enzyme test (Architect[®] anti-HCV assay — Germany) in serum samples on a i4000 instrument (Architect System, United States of America [USA]). Test results were analyzed according to the manufacturer's instructions.

Based on the results of the above cross-sectional survey, we planned this case-control study during the period of March through May 2018 to investigate the risk factors associated anti-HCV seropositivity among men incarcerated in the closed




Fig. 1 – Geographic locations of the penitentiaries included in the study in Paraná, Brazil. PEL, State Penitentiary of Londrina; CRESLON, Social Reintegration Center of Londrina; PEP, State Penitentiary of Piraquara; PCE, Central State Penitentiary; CCJP, House of Custody of São José dos Pinhais; CCC, House of Custody of Curitiba; CCP, House of Custody of Piraquara; CMP, Criminal Medical Complex; PFB, State Penitentiary of Francisco Beltrão; RM, Metropolitan Region of Curitiba.




Fig. 2 – Flowchart of the recruitment process for the prevalence study and the screening process of cases and controls.

regime of the penitentiary system of Paraná, Brazil. In the first study, 30 prisoners anti-HCV reactive were identified. Out of these, 27 cases from eight penitentiaries of Paraná were matched for same penitentiary, time of imprisonment within five years, and age within three years with 54 control subjects. Three cases were excluded because it was not possible to find matched controls for them. A case was defined as any inmate with reactive serology for HCV. Controls were selected from among prisoners with serologic markers for non-reactive HCV. A flowchart of the recruitment strategy is shown in Fig. 2.

After cases and controls selection, the following information was obtained: race/color, marital status, schooling, occupation when incarcerated, number of times in prison, conviction time, STD history, knowledge about hepatitis B and C transmission routes, blood transfusion history, tattoo and piercing history, illicit drug use, injectable drug use, condom use, alcoholic beverage use, sexual orientation, homosexual relationship history, and intimate visit history. Anonymous identification numbers were used to cross-reference the information contained in the questionnaires.

All processing and analysis steps were performed with the Statistical Package for Social Science, version 24.0 (SPSS Inc., Chicago, IL, USA) program. Absolute (n) and relative (%) frequencies are used to describe the sample features. Initial comparisons between groups were performed by factorial ANOVA (groups vs penitentiaries). Comparisons between cases and controls for categorical variables were performed using chi-square tests with continuity correction. Variables that presented $p < 0.20$ in univariate analysis were included into a binary logistic regression model to identify independent risk factors for HCV infection ($p < 0.05$).

Results

HCV seroprevalence identified in the survey "Prevalence of HIV and Hepatitis B and C in the prison population of the Paraná State Penitentiaries" was 2.7% (95%CI 1.9-3.8). Cases ($n=27$) and controls ($n=54$), selected concomitantly, were not significantly different in terms of penitentiary, age, and time of imprisonment (Table 1).

Table 2 shows the general characteristics of the two groups. The mean age was 39 years, and positive serology was predominantly found among individuals over 30 years of age. Although the differences were not statistically significant, the cases had a higher prevalence of unemployment, had been in prison more often, reported greater knowledge about hepatitis, and had higher prevalence of blood transfusions, illicit drug use, and homosexual relationships than the controls. However, the only variable independently associated with anti-HCV seropositivity after multivariate analysis was injectable drug use (OR: 4.0 95%CI 1.41-11.35).

Four variables with a $p < 0.20$ (Table 2) were included in the logistic regression model to identify independent risk factors for anti-HCV reagent (Table 3). Of these, two variables persisted significantly associated: illicit drug use and injectable drug use. As the two presented high collinearity (those who used illicit drugs were the same individuals who used injectable drugs), construction of a multiple regression model was not possible. However, given the narrow confidence interval

of the OR in the initial analysis, injecting drug use is the main risk factor for hepatitis C infection in prisoners.

There have been few studies in Brazilian male prisons assessing risk factors for hepatitis C infection.¹ Most of these studies have aimed just to determine the prevalence of HCV seromarkers.¹² Therefore, among the contributions of this study, we highlight the case-control design with representation of prisoners in 11 closed-regime male penitentiaries in the state of Paraná. It is worth mentioning that this is the first study in the state that shows a clear view of the prevalence of HCV and the risk factors related to exposure among prisoners.

The prison population is considered to be at high risk for acquiring infectious diseases^{1,25} because prisoners are confined and present risky behavioral factors such as low educational level,²⁵ irregular and infrequent use of condoms, multiple sexual partners, sex under the influence of alcohol and drugs,²⁶⁻²⁸ and irregular use of preventive measures.¹ These risk factors and behaviors can precede arrest and frequently continue during incarceration.^{18,29}

Prisoners with a history of previous incarcerations have had a greater opportunity to acquire HCV infection than those who have not been previously incarcerated.^{1,18} Several studies have revealed that previous history of incarceration is related to frequent exposure to high-risk activities such as unsafe lifestyles, risky sexual behaviors, exposure to sharps for tattooing, and sharing of needles, syringes and other paraphernalia for illicit drug use.^{1,12,18,25}

Recently, Stone et al. published a systematic review and meta-analysis of 41 studies on this subject. It has been identified that both recent and past incarceration contribute to an increased risk of HCV acquisition ranging from 21% to 62%.³⁰ In the present study, previous incarceration was significantly associated with HCV infection in univariate analysis. However, this factor was not considered an independent predictor of viral infection, suggesting that there must be other factors that confound the relationship between these two variables.²⁹

Studies have identified that homosexual relationship offer a greater chance of HCV infection than heterosexual relationship; in our study, in the final model, this association was not confirmed.²⁸⁻³² It is believed that this association may be related to risk behaviors rather than to homosexuality itself, according to Reekie et al.³³

In this study, illicit drug use was associated with HCV exposure. These findings have also been identified in other studies worldwide and in Brazil.^{18,25,29,32} Despite the significance of illicit drug use in univariate analysis, in the final model only injecting drug use was associated with positive serology for HCV, since those who used illicit drugs were the same individuals who used injecting drugs (collinearity). In our study, the odds of contracting hepatitis C were four-fold higher for men who used injecting drugs (OR = 4.00; 95%CI: 1.41-11.35) than for prisoners in the same prison system who did not inject drugs. Injecting drug-using prisoners and males in a meta-analysis study were 24 times more likely to be HCV-positive than non-injecting drug users.²⁶

Worldwide, there is a continuing epidemic of HCV infection among young white adults who inject drugs, are aged less than 30 years, and with a history of previous or simultaneous opiate consumption.^{33,34} HCV infection prevalence is 10-15 times higher among people who inject drugs, with

Table 1 – Description of the paired variables of the cases (27) and controls (54) according to the penal unit, average age, and prison time in the state prisons of Paraná.

Penitentiary	Sample N		Average age		Average prison time	
	Case	Control	Case	Control	Case	Control
PFB	01	02	32 ^a	31,00 ± 1.14	9 ^a	7 ± 0.00
PEL I	02	04	45.50 ± 2.12	45.25 ± 2.63	4.50 ± 2.12	5.00 ± 3.74
PEL II	04	08	45.25 ± 11.53	44.63 ± 10.24	3.50 ± 2.08	3.75 ± 2.60
PEC	07	14	42.29 ± 8.14	42.21 ± 7.89	4.71 ± 2.69	5.36 ± 3.93
PEP II	05	10	32.60 ± 9.81	33.10 ± 8.60	1.80 ± 1.92	2.00 ± 2.40
CCC	03	06	39.33 ± 3.78	38.17 ± 3.43	1.67 ± 2.08	2.00 ± 1.26
CCP	03	06	30.67 ± 9.02	30.67 ± 8.07	0.33 ± 0.57	0.16 ± 0.40
CMP	02	04	39.50 ± 0.71	44.50 ± 11.03	0.50 ± 0.71	0.75 ± 1.50
Total	27	54	38.96 ± 9.10	39.13 ± 9.26	14.25 ± 14.06	15.11 ± 12.63

Effects of ANOVA information for case vs control: age ($F = 0.017$; $p = 0.896$) and prison time ($F = 0.001$; $p = 0.999$).

^a Just one subject.

higher rates among new injectors. A quarter of injecting drug users will be infected within two years after starting. In addition, HCV is approximately 10 times more infectious than HIV, and injecting drug use increases the risk by 3–10% compared to 0.3% for HIV contamination. Furthermore, the virus remains infective in liquid and syringes and on inanimate surfaces for weeks.^{35–37}

The relationship between illicit drug use, HCV infection and imprisonment is very close, as injecting drug users (IDUs) are the individuals with the highest rates of incarceration due to involvement in illicit activities, and they get involved criminal activities to finance their addictions.³⁸ A recent meta-analysis of six published studies on the incidence of HCV in prisoners reported that the risk of HCV infection was eight times higher in injecting drug-using prisoners than in injecting drug-using non-prisoners.³⁰

In a cohort of 735 Australian prisoners with a history of injecting drug use that were followed for more than 14 years, 55.1% of prisoners were found to have some history of HCV, and 47.4% of those tested in the prison were seropositive for HCV. In this study, drug injection in prison was found to be strongly associated with HCV seropositivity by Snow et al.⁹ Roux et al. also reported injecting drug use in 99% of cases in their survey of sociodemographic and behavioral characteristics of participants tested for HCV infection in a prison population in southwestern France.³⁹

In Latin America and the Caribbean, 11.3% of prisoners coinfecting with HIV and hepatitis C use injecting drugs, and in Brazil, the prevalence is approximately 9.2%.⁴⁰ In Brazilian studies, there are reports of syringe sharing for drug use in 32.5% of prisoners. The use of illicit drugs is common in prison environments, and even when the use of only inhaled illicit drugs has been reported, high frequency of use ends up being a bridge to injectable drug use.⁴¹ Pereira et al., in their study on populations from 26 Brazilian states and the Federal District, showed in a multivariate model that use of injectable drugs (OR = 6.65; 95%CI: 2.47–17.91) and of inhaled drugs (OR = 2.59; 95%CI: 1.34–5.81) were predictive factors for HCV infection.⁴¹

The epidemiological impact of various risk factors for acquiring HCV infection has been investigated in a number of studies on prison populations, and injecting drugs has been found to be the main risk factor associated with HCV infection

in prison populations.^{9,10,30,37} Although such risk behavior is strictly prohibited in prisons around the world, almost half of illicit drug users continue to use such substances after arrest. In addition, the difficulty in obtaining sterile injecting equipment in prison results in widespread sharing of infected equipment and increased risk of HCV transmission.¹²

It should be clarified that the use of injecting drugs is also a risk factor outside the prison environment. In developed countries, most new HCV infections are reported in injecting drug users. The most recent surveys of active IDUs in the United States indicate that approximately one third of young users (ages 18–30) are infected with HCV.⁴²

The seroprevalence of HCV observed in this study was 2.7%, which is higher than that in the range of 0.7% and 1.38% reported among people aged 10–69 years.^{41,43,44} In this study, HCV seroprevalence was slightly higher than that found in a study by Puga et al.¹⁸ among men in penitentiaries in the state of Mato Grosso do Sul (2.4%), but lower from the rates found in studies on prisoners in the states of São Paulo (8.7%) and Minas Gerais (6.34%).^{24,45} The prevalence of HCV infection among prisoners in Paraná was also lower than that found in studies in Australia (29%), England (24.2%), Italy (22.4%), Ghana (18.7%), Iran (7.4%), and Lebanon (3.4%).^{46–48}

The presence of HCV can be manifested as an acute infection, with development of symptoms in 20–30% of cases, or as a chronic infection that can result in liver fibrosis, cirrhosis, or hepatocellular carcinoma in 70–80% of cases.^{33,34} The possibility of infection without apparent symptoms makes it difficult to diagnose infection early and, consequently, postpones diagnosis and treatment of chronic patients. This situation of delayed diagnosis is frequent within the prison system since the infrastructure and health services in the system to care for the prisoner are poor, when existent.⁴⁸ There is also an absence of educational campaigns and guidance for the practice of safe sex, sexual transmission among men who have sex with other men (HSH) is higher in the prison environment than in the outside environment, reaching rates of 8.6%. In relation to the HIV-positive prisoners, a report from Israel showed a rate of 6.5% among HSH who had anal sex before imprisonment.⁴⁹

Educational campaigns and guidelines for the practice of safe sex among the prison population would be useful for

Table 2 – Sociodemographic characteristics, risk factors, prison variables and HCV infection among male prisoners of the penitentiaries of the state of Paraná, Brazil (n = 81).

	Cases (n = 27)		Control (n = 54)		p-Value
	n	%	n	%	
Skin color					
White	13	48.1	29	53.7	0.814
Other	14	51.9	25	46.3	
Marital state					
Married/cohabitating	11	40.7	28	51.9	0.479
Single/divorced	16	59.3	26	48.1	
Education					
Incomplete elementary school	14	51.9	27	50.0	0.875
Complete elementary education	13	48.1	27	50.0	
Were employed					
Yes	9	33.3	26	48.1	0.303
No	18	66.7	28	51.9	
Number of times in the prison system					
Up to 2 times	5	18.5	19	35.2	0.197
More than 2 times	22	81.5	35	64.5	
Conviction time					
Up to 12 years	15	55.6	26	48.1	0.694
More than 12 years	12	44.4	28	51.9	
DST history					
Yes	11	40.7	26	48.1	0.693
No	16	59.3	28	51.9	
Knowledge about hepatitis					
Yes	14	51.9	20	37.0	0.301
No	13	48.1	34	63.0	
Blood transfusion					
Yes	7	25.9	8	14.8	0.363
No	20	74.1	46	85.2	
Tattooing					
Yes	19	70.4	32	59.3	0.464
No	8	29.6	22	40.7	
Piercing					
Yes	5	18.5	12	22.2	0.923
No	22	81.5	42	77.8	
Illicit drugs use					
Yes	24	88.9	36	66.7	0.060
No	3	11.1	18	33.3	
Injecting drug use					
Yes	12	44.4	9	16.7	0.016
No	15	55.6	45	83.3	
Condoms use					
Yes	14	51.9	32	59.3	0.418
No	4	14.8	9	16.7	
Do not know	9	33.3	13	24.1	
Alcohol consumption					
Yes	24	88.9	49	90.7	0.794
No	3	11.1	5	9.3	
Sexual orientation					
Heterosexual	25	92.6	47	87.0	0.708
Other	2	7.4	7	13.0	
Homosexual relationship					
Yes	5	18.5	3	5.6	0.148
No	22	81.5	51	94.4	
Intimate visit					
Yes	7	25.9	19	35.2	0.556
No	20	74.1	35	64.8	

STD, sexually transmitted diseases; Fr, frequency.

Table 3 – Independent hepatitis C predictors of anti-HCV seropositivity in men arrested in the penitentiary system in Paraná by multivariate logistic regression analysis.

	OR _{br} (IC 95%)	p
Number of times in the prison system		
Up to 2 times	1	
More than 2 times	2.39 (0.78–7.32)	0.128
Illicit drugs use		
Yes	4.00 (1.06–15.08)	0.041
No	1	
Injecting drug use ^a		
Yes	4.00 (1.41–11.35)	<0.001
No	1	
Homosexual relation		
Yes	3.86 (0.85–17.60)	0.081
No	1	

^a Main variable in the final model.

reducing the prevalence rates of HCV and other sexually transmissible diseases. Lack of healthy behavior is related to the low effectiveness of the medical teams in prison environments, which hinders medical care, since prisons are environments characterized by conditions of insecurity and fear.⁵⁰

This study has limitations because some behavioral risks may have been underreported by the participants due to the fact that vulnerability can lead to discrimination and stigmatization. Such underreporting could have contributed to underestimation of the potential risk factors associated with HCV exposure.

In conclusion, we observed injectable drug use to be the main risk factor for hepatitis C infection in men incarcerated in the penitentiary system of Paraná state, Brazil. The increased risk was associated with a high frequency of risky behavior before and during incarceration, especially for injecting drug users. These results suggest an urgent need for effective prevention programming, education, prison strategies, and programs adapted to local contexts as well as new direct-acting antiviral drugs, treatment strategies, and therapies.

Serological testing for screening and monitoring of IDUs and treatment of drug abuse and addiction among prisoners in need in the prison system would make it possible to evaluate the success of harm reduction strategies (needle/syringe sharing programs for injecting drugs and tattoos). Finally, studies using phylogenetic analysis will also enhance understanding of the routes of HCV transmission in this population.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgement

This research was funded by the Ministry of Health (Brazilian Government) and Western Paraná State University (UNIOESTE) under agreement 797322/2013.

REFERENCES

- Magri MC, Ibrahim KY, Pinto WP, et al. Prevalence of hepatitis C virus in Brazil's inmate population: a systematic review. *Rev Saude Publica*. 2015;49, <http://dx.doi.org/10.1590/S0034-8910.2015049005886>. Available from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544450/pdf/0034-8910-rsp-S0034-89102015049005886.pdf>. [Cited 15 August 2018].
- Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis. *Harm Reduct J*. 2018;15:1–9. Available from: <https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-018-0231-0>. [Cited 29 November 2018].
- Sequera VG, Valencia S, García-basteiro AL, Marco A, Bayas JM. Vaccinations in prisons: a shot in the arm for community health. *Hum Vaccin Immunother*. 2015;11:2615–26. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685700/>. [Cited 13 December 2018].
- Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *Lancet*. 2016;388:1089–102. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)30466-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30466-4/fulltext). [Cited 2 April 2018].
- Brandolini M, Novati S, Silvestri A, et al. Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting. *BMC Public Health*. 2013;13:1–6. Available from: <https://bmcpublihealth.biomedcentral.com/articles/10.1186/1471-2458-13-981>. [Cited 12 December 2018].
- Prasetyo AA, Dirgahayu P, Sari Y, Hudiyo H, Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. *J Infect Dev Ctries*. 2013;7:453–67. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23771289>. [cited 29 November 2018].
- Azbel L, Wickersham JA, Wegman MP, et al. Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. *Drug Alcohol Depend*. 2015;1:68–75. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/25861943>. [Cited 20 June 2018].
- Falquetto TC, Endringer DC, Andrade TU, Lenz D. Hepatitis C in prisoners and non-prisoners in Colatina, Espírito Santo, Brazil. *Braz J Pharm Sci*. 2013;49, <http://dx.doi.org/10.1590/S1984-82502013000400013>. Available from: <http://www.scielo.br/scielo.php?script=sci.arttext&pid=S1984-82502013000400013>. [Cited 20 November 2018].
- Snow KJ, Young JT, Preen DB, Lennox NG, Kinner SA. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs. *BMC Public Health*. 2014;14, <http://dx.doi.org/10.1186/1471-2458-14-830>. Available from: <https://bmcpublihealth.biomedcentral.com/articles/10.1186/1471-2458-14-830>. [Cited 18 August 2018].
- Dolan K, Teutsch S, Scheuer N, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. *Eur J Epidemiol*. 2010;25:143–8. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20084429>. [Cited 29 November 2018].
- Pompilio MA, Pontes ERJC, Castro ARCM, et al. Prevalence and epidemiology of chronic hepatitis C among prisoners of Mato Grosso do Sul State, Brazil. *J Venom Anim Toxins Incl Trop Dis*. 2011;17:216–22. Available from: <http://www.scielo.br/scielo.php?script=sci.arttext&pid=S1678-91992011000200013>. [Cited 20 October 2018].

12. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. *World J Hepatol.* 2015;7:2323–30. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577639/>. [Cited 13 August 2018].
13. Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. *World J Gastroenterol.* 2015;21:10790–810. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600581/>. [Cited 30 November 2018].
14. Gois SM, Santos Junior HPO, Silveira MFA, Gaudencio MMP. Para além das grades e punições: uma revisão sistemática sobre a saúde penitenciária. *Ciênc Saúde Coletiva.* 2012;17:1235–46. Available from: <http://www.scielo.br/scielo.php?pid=S1413-81232012000500017&script=sci.abstract&tlng=pt>. [Cited 10 September 2018].
15. Mohamed HI, Saad ZM, Abd-Elreheem EM, et al. Hepatitis C, hepatitis B and HIV infection among Egyptian prisoners: seroprevalence, risk factors and related chronic liver diseases. *J Infect Public Health.* 2013;6:186–95. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23668463>. [Cited 18 November 2018].
16. Alvarez KJ, Befus M, Herzog CT, Larson E. Prevalence and correlates of hepatitis C virus infection among inmates at two New York state correctional facilities. *J Infect Public Health.* 2014;7:517–21. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/25182508>. [Cited 15 August 2018].
17. Wenger PJ, Rottnek F, Parker T, Crippin JS. Assessment of hepatitis C risk factors and infection prevalence in a jail population. *Am J Public Health.* 2014;104:1722–7. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/25033142>. [Cited 30 November 2018].
18. Puga MAM, Bandeira LM, Pompilio MA, et al. Prevalence and incidence of HCV infection among prisoners in central Brazil. *PLoS One.* 2017;12:1–14. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169195>. [Cited 12 June 2018].
19. Moradi G, Gouya MM, Azimizan Zavareh F, et al. Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio-behavioural surveillance survey in 2015. *Trop Med Int Health.* 2018;23:641–9. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29698576>. [Cited 8 December 2018].
20. Ramezani A, Amirmoezi R, Volk JE, et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. *AIDS Care.* 2014;26:1122–6. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/24499303>. [Cited 8 December 2018].
21. Ministério da Saúde, Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Doenças Sexualmente Transmissíveis, Aids e Hepatites Virais. *Manual Técnico para o Diagnóstico das Hepatites Virais.* Ministério da Saúde: Brasília; 2016.
22. Belaunzarán-Zamudio PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, Ahmed S, Beyrer C. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. *PLoS One.* 2017;12:e0179931. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179931>. [Cited 27 November 2018].
23. Aisyah DN, Shallcross L, Hayward A, Aldridge RW, Hemming S, Yates S. Hepatitis C among vulnerable populations: a seroprevalence study of homeless, people who inject drugs and prisoners in London. *J Viral Hepat.* 2018;25:1260–9. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(17\)32953-7/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32953-7/fulltext). [Cited 18 November 2018].
24. Instituto Brasileiro de Geografia e Estatística — IBGE. População residente — Censo Demográfico 2010. Rio de Janeiro; 2010. Available from: https://ww2.ibge.gov.br/home/estatistica/populacao/censo2010/indicadores_sociais_municipais/indicadores_sociais_municipais_tab.uf.zip.shtm. [9 Mai 2019].
25. Coelho HC, Oliveira SAN, Miguel JC, et al. Predictive markers for hepatitis C virus infection among Brazilian inmates. *Rev Soc Bras Med Trop.* 2009;42:369–72. Available from: <http://www.scielo.br/scielo.php?script=sci.arttext&pid=S0037-86822009000400002>. [Cited 4 February 2019].
26. Vescio MF, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *J Epidemiol Community Health.* 2008;62:305–13. Available from: <https://jech.bmj.com/content/62/4/305.long>. [Cited 2019].
27. Silva AAS, Araújo TME, Teles SA, Magalhães RLB, Andrade ELR. Prevalência de hepatite B e fatores associados em internos de sistema prisional. *Acta Paulista de Enfermagem.* 2017;30:66–72. Available from: <http://www.scielo.br/scielo.php?script=sci.arttext&pid=S0103-21002017000100066&lng=pt>. [Cited 2019].
28. Marx MA, Murugavel KG, Tarwater PM, et al. Association of hepatitis C virus infection with sexual exposure in Southern India. *Clin Infect Dis.* 2003;37:514–20. Available from: <https://academic.oup.com/cid/article/37/4/514/331244>. [Cited 2019].
29. Kassaian N, Adibi P, Kafashaian A, et al. Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran. *Int J Prev Med.* 2012;3:S156–61. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399300/PMCID:PMC3399300>. [Cited 2019].
30. Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. *Lancet Infect Dis.* 2018;18:1397–409. Available from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(18\)30469-9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30469-9/fulltext). [Cited 2019].
31. Teutsch S, Luciani F, Scheuer N, et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. *BMC Public Health.* 2010;10, <http://dx.doi.org/10.1186/1471-2458-10-633>. Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-10-633>. [Cited 16 August 2018].
32. Santos BFO, Santana NO, Franca AVC. Prevalence, genotypes and factors associated with HCV infection among prisoners in Northeastern Brazil. *World J Gastroenterol.* 2011;17:3027–34. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132254/>. [Cited 2019].
33. Reekie JM, Levy MH, Richards AH, et al. Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners — 2004, 2007, 2010. *Med J Aust.* 2014;200:277–80. Available from: <https://www.mja.com.au/journal/2014/200/5/trends-hiv-hepatitis-b-and-hepatitis-c-prevalence-among-australian-prisoners>. [Cited 10 July 2018].
34. Martinello M, Matthews GV. Enhancing the detection and management of acute hepatitis C virus infection. *Int J Drug Policy.* 2015;26:899–910. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/26254495>. [Cited 20 August 2018].
35. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. *J Infect Dis.* 2010;202:984–90. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20726768>. [Cited 12 July 2018].

36. Doerrbecker J, Friesland M, Ciesek S, et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. *J Infect Dis.* 2011;204:1830–8. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/22013220>. [Cited 10 September 2018].
37. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis virus infection in young adult injectors: using evidence to inform comprehensive prevention. *Clin Infect Dis.* 2013;57:S32–8. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23884063>. [Cited 12 September 2018].
38. Hunt DR, Saab S. Viral hepatitis in incarcerated adults: a medical and public health concern. *Am J Gastroenterol.* 2009;104:1024–31. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/19240708>. [Cited 10 June 2018].
39. Roux P, Sagaon-Teyssier L, Lions C, Fugon L, Verger P, Carrieri MP. HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. *BMJ Open.* 2014;4, <http://dx.doi.org/10.1136/bmjopen-2014-005694>. Available from: <https://bmjopen.bmj.com/content/4/10/e005694>. [Cited 14 August 2018].
40. Moazen B, SaeediMoghaddam S, Silbernagl MA, et al. Prevalence of drug injection, sexual activity, tattooing, and piercing among prison inmates. *Epidemiol Ver.* 2018;40:58–69. Available from: <https://academic.oup.com/epirev/article-abstract/40/1/58/4979520?redirectedFrom=fulltext>. [Cited 2 February 2019].
41. Pereira LM, Martelli CM, Moreira RC, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. *BMC Infect Dis.* 2013;13:1–12. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23374914>. [Cited 7 December 2018].
42. Prussing C, Bornschlegel K, Balter S. Hepatitis C surveillance among youth and young adults in New York city, 2009–2013. *J Urban Health.* 2015;92:387–99. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/25450518>. [Cited 2 February 2019].
43. Martins T, Narciso-Schiavon JL, Schiavon LL. Epidemiologia da infecção pelo vírus da hepatite C. *Rev Assoc Med Bras.* 2011;57:107–12. Available from: <http://www.scielo.br/scielo.php?script=sci.arttext&pid=S0104-42302011000100024&lng=en>. [Cited 15 December 2018].
44. Rodrigues Neto J, Cubas MR, Kusma SZ, Olandoski M. Prevalência da hepatite viral C em adultos usuários de serviço público de saúde do município de São José dos Pinhais — Paraná. *Rev Bras Epidemiol.* 2012;15:627–38. Available from: <http://www.scielo.br/scielo.php?script=sci.arttext&pid=S1415-790X2012000300016>. [Cited 9 December 2018].
45. Catalan-Soares BC, Almeida RTP, Carneiro-Proietti ABF. Prevalência do HIV-1/2, do HTLV-1/II, do vírus da hepatite B (HBV) e C (HCV), do *Treponema pallidum* e do *Trypanosoma cruzi* entre presidiários em Manhuaçu, Minas Gerais, Brasil. *Rev Soc Bras Med Trop.* 2000;33:27–30. Available from: <http://www.scielo.br/scielo.php?pid=S0037-86822000000100004&script=sci.abstract&tlng=pt>. [Cited 16 June 2018].
46. Adjei AA, Armah HB, Gbagbo F, et al. Correlates of hepatitis C virus infection among incarcerated Ghanaians: a national multicentre study. *J Med Microbiol.* 2007;56(391). Available from: <https://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.46859-0>. [Cited 10 June 2018].
47. Kirwan P, Evans B, Sentinel Surveillance of Hepatitis Testing Study Group, Brant L. Hepatitis C and B testing in english prisons is low but increasing. *J Public Health (Oxf).* 2011;33:197–204. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/21345883>. [Cited 16 June 2018].
48. Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. *Best Pract Res Clin Gastroenterol.* 2012;26:413–27. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23199501>. [Cited 14 June 2018].
49. Moazen B, Saeedi Moghaddam S, Silbernagl MA, et al. Prevalence of drug injection, sexual activity, tattooing, and piercing among prison inmates. *Epidemiol Rev.* 2018;40:58–69. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29860343>. [Cited 11 June 2018].
50. Minayo MCS, Ribeiro AP. Condições de saúde dos presos do estado do Rio de Janeiro, Brasil. *Ciênc Saúde Coletiva.* 2016;21:2031–40. Available from: <http://www.scielo.br/scielo.php?pid=S1413-81232016000702031&script=sci.abstract&tlng=pt>. [Cited 13 December 2018].